World Journal of Urology

, Volume 30, Issue 5, pp 701–706 | Cite as

The result of adjuvant chemotherapy for localized pT3 upper urinary tract carcinoma in a multi-institutional study

  • Atsunari Kawashima
  • Yasutomo Nakai
  • Masashi Nakayama
  • Takeshi Ujike
  • Go Tanigawa
  • Yutaka Ono
  • Akihito Kamoto
  • Tsuyosi Takada
  • Yuichiro Yamaguchi
  • Hitoshi Takayama
  • Kazuo Nishimura
  • Norio Nonomura
  • Akira TsujimuraEmail author
Original Article



To determine through the analysis of our multi-institutional database whether postoperative adjuvant chemotherapy for upper urinary tract carcinoma with localized invasive upper urinary tract carcinoma (UUTC) is beneficial.


A study population of 93 patients with pT3N0/xM0 UUTC was eligible for this study. Clinical features evaluated were sex, tumor location, adjuvant chemotherapy status, tumor pathology (histology, grade, infiltrating growth, lymphovascular invasion (LVI)), and cause of death. Cancer-specific survival (CSS) was estimated by Kaplan–Meier method. Prognostic factors related to CSS were analyzed by Cox proportional hazards regression model for multivariate analysis.


In pT3 patients, overall 5-year CSS rate was 68.4% and median CSS time was 31 months (range 3–114 months). In the adjuvant chemotherapy group, 5-year CSS rate was 80.8%, whereas 5-year CSS rate was 64.4% in the non-adjuvant chemotherapy group. By multivariate analysis, adjuvant chemotherapy status was significantly associated with CSS (P = 0.008) were sex, tumor grade, tumor histology, and LVI presence.


This study, although it was retrospective study, revealed that adjuvant chemotherapy after RNU may be beneficial in pT3N0/X patients by multivariate analysis. Prospective studies evaluating adjuvant therapy regimens for UTTC are required.


Upper urinary tract Urothelial carcinoma Adjuvant chemotherapy Retrospective study Prognostic factor 



Upper urinary tract


Computed tomography


Magnetic resonance imaging


Radical nephroureterectomy


Carcinoma of upper urinary tract


Cancer-specific survival


Recurrence-free survival


The American Joint Committee on Cancer


Union Internationale Contre le Cancer


Lymphovascular invasion


Infiltrating growth


Estimated glomerular filtration rate


Methotrexate, vinblastine, doxorubicin, and cisplatin


Gemcitabine and cisplatin


Methotrexate, epirubicin, and cisplatin


Methotrexate, epirubicin, and nedaplatin


Hazard ratio


Confidence interval



The authors wish to thank the investigators, their staff, and the affiliated institutions for the important contribution to this study in The Osaka Urinary Tract Urothelial Carcinoma Collaboration Group: Kensaku Nishimura, Susumu Miyoshi, (Osaka Rosai Hospital); Ken Takeda, (Osaka Medical Center for Cancer and Cardiovascular Diseases); Seiji Yamaguchi, (Osaka General Medical Center Hospital); Yoichi Shiotsuka, Shigeru Nakamori, (Higashiosaka City General Hospital); Toshiaki Yoshioka, (Sumitomo Hospital); Satoko Fukuda, Tsuneo Hara, (Ikeda Municipal Hospital); Hideki Sugao, (Minoh City Hospital); Mototaka Sato, Koji Hatano, Masatoshi Mukai, Akira Nagahara, Motohide Uemura, Daizo Oka, (Osaka University).

Conflict of interest

There are no sources of support to declare, and no author has any financial disclosures or conflicts of interest to declare.


  1. 1.
    Raman JD, Scherr DS (2007) Management of patients with upper urinary tract transitional cell carcinoma. Nat Clin Pract Urol 4:432–443PubMedCrossRefGoogle Scholar
  2. 2.
    Hall MC, Womack S, Sagalowsky AI et al (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52:594–601PubMedCrossRefGoogle Scholar
  3. 3.
    Michael M, Tannock IF, Czaykowski PM et al (1998) Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience. Br J Urol 82:366–372PubMedCrossRefGoogle Scholar
  4. 4.
    Lee SE, Byun SS, Park YH et al (2006) Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract. Urol Int 77:22–26PubMedCrossRefGoogle Scholar
  5. 5.
    Hellenthal NJ, Shariat SF, Margulis V et al (2009) Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 182:900–906PubMedCrossRefGoogle Scholar
  6. 6.
    Greene FL, Page DL, Fleming ID et al (2002) American Joint Committee on Cancer (AJCC) staging manual, 6th edn. Springer, PhiladelphiaGoogle Scholar
  7. 7.
    Mostofi FK, Sobin LH, Torioni H (1973) Histological typing of urinary bladder tumors. World Health Organization, GenevaGoogle Scholar
  8. 8.
    Matsuo S, Imai E, Horio M et al (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992PubMedCrossRefGoogle Scholar
  9. 9.
    Lane BR, Smith AK, Larson BT et al (2010) Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer 15:2967–2973CrossRefGoogle Scholar
  10. 10.
    Park S, Hong B, Kim CS et al (2004) The impact of tumor location on prognosis of transitional cell carcinoma of the upper urinary tract. J Urol 171:621–625PubMedCrossRefGoogle Scholar
  11. 11.
    Kim DS, Lee YH, Cho KS et al (2010) Lymphovascular invasion and pT stage are prognostic factors in patients treated with radical nephroureterectomy for localized upper urinary tract transitional cell carcinoma. Urology 75:328–332PubMedCrossRefGoogle Scholar
  12. 12.
    Bamias A, Deliveliotis Ch, Fountzilas G et al (2004) Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group. J Clin Oncol 22:2150–2154PubMedCrossRefGoogle Scholar
  13. 13.
    Bolenz C, Fernández MI, Trojan L et al (2008) Lymphovascular invasion and pathologic tumor stage are significant outcome predictors for patients with upper tract urothelial carcinoma. Urology 72:364–369PubMedCrossRefGoogle Scholar
  14. 14.
    Novara G, Matsumoto K, Kassouf W et al (2010) Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 57:1064–1071PubMedCrossRefGoogle Scholar
  15. 15.
    Kikuchi E, Margulis V, Karakiewicz PI et al (2008) Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 27:612–618PubMedCrossRefGoogle Scholar
  16. 16.
    Kondo T, Nakazawa H, Ito F et al (2007) Impact of the extent of regional lymphadenectomy on the survival of patients with urothelial carcinoma of the upper urinary tract. J Urol 178:1212–1217PubMedCrossRefGoogle Scholar
  17. 17.
    Roscigno M, Shariat SF, Margulis V et al (2009) Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol 181:2482–2489PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Atsunari Kawashima
    • 1
  • Yasutomo Nakai
    • 1
  • Masashi Nakayama
    • 2
  • Takeshi Ujike
    • 3
  • Go Tanigawa
    • 4
  • Yutaka Ono
    • 5
  • Akihito Kamoto
    • 6
  • Tsuyosi Takada
    • 7
  • Yuichiro Yamaguchi
    • 8
  • Hitoshi Takayama
    • 1
  • Kazuo Nishimura
    • 2
  • Norio Nonomura
    • 1
  • Akira Tsujimura
    • 1
    Email author
  1. 1.Department of UrologyOsaka University Graduate School of MedicineSuita City, OsakaJapan
  2. 2.Department of UrologyOsaka Medical Center for Cancer and Cardiovascular DiseasesOsakaJapan
  3. 3.Department of UrologyOsaka Rosai HospitalOsakaJapan
  4. 4.Department of UrologyOsaka General Medical Center HospitalOsakaJapan
  5. 5.Department of UrologyHigashiosaka City General HospitalOsakaJapan
  6. 6.Department of UrologySumitomo HospitalOsakaJapan
  7. 7.Department of UrologyIkeda Municipal HospitalOsakaJapan
  8. 8.Department of UrologyMinoh City HospitalOsakaJapan

Personalised recommendations